PHILADELPHIA — Patents related to two of the University of Pennsylvania’s Juxtapid high-cholesterol treatment methods were upheld by the Patent Trial and Appeal Board after they were challenged by hedge fund manager Kyle Bass’ Coalition for Affordable Drugs.  

Kerry S. Taylor, partner at Knobbe, Martens, Olson & Bear LLP, said the fact that the board gave weight to UPenn’s commercial success in its decision to uphold the patents is “noteworthy.”

“In the (U.S. Patent and Trademark Office’s inter partes review) proceedings, their holdings on obviousness are rarely swayed by ‘secondary consideration’ of non-obviousness, such as commercial success,” Taylor told the Pennsylvania Record. “The board found UPenn’s argument of a lack of expectation of success to be convincing, particularly in conjunction with UPenn’s evidence of commercial success.”

UPenn said Juxtapid had generated $420 million in revenue, but the coalition claimed that the commercial success of the method had no bearing on its challenge.

In addition to considering the commercial success of the patented methods, the board also based its decision on a finding that a slide deck provided by the coalition to investors and, eventually, webpage viewers, did not qualify as a “printed publication” in accordance with patent laws.

UPenn claimed that the slide deck did not constitute a printed publication because the audience was not “skilled in the relevant art and because there was insufficient evidence of the public availability of the slide deck,” Taylor and Knobbe Martens colleague Mark Davis said in a piece written for

However, the coalition argued to the board that the slide deck was a printed publication because it could be downloaded by the public “shortly after” it was submitted to investors.

Taylor said Bass announced several years ago that he would be filing challenges to drug patents under the USPTO’s new inter partes review (IPR) procedures.

“Roughly speaking, Kyle Bass’ challenges have about a 50 percent to 60 percent success rate of the IPR being instituted and about a 30 percent success rate of challenged claims being found unpatentable,” Taylor said. The IPR works as a threshold decision to enter the proceeding.

Taylor said universities such as UPenn do sometimes find themselves subject to patent challenge proceedings, although he was not sure how often that occurs.

“However, the USPTO recently held that a state university could not be challenged in view of its state sovereign immunity,” Taylor said. “UPenn, however, is a private university, so that would not have mattered for this case.”

Want to get notified whenever we write about University of Pennsylvania ?
Next time we write about University of Pennsylvania, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

University of Pennsylvania

More News